In vitro glycoengineering of a monoclonal antibody produced in insect cells
Sugar modifications, in particular, N-glycans, largely determine protein quality, functionality, and, in case of therapeutic biomolecules, safety. Therapeutic monoclonal antibodies (mAbs) generate immune response through effector functions, for which they require complex N-glycans with high levels o...
| Päätekijä: | |
|---|---|
| Muut tekijät: | , , , , , |
| Aineistotyyppi: | Pro gradu |
| Kieli: | eng |
| Julkaistu: |
2024
|
| Aiheet: | |
| Linkit: | https://jyx.jyu.fi/handle/123456789/96162 |